RecruitingPhase 3NCT03955445
Renal
C3 glomerulonephritis
7
studies recruiting now
as of 7 Sept 2026
27
studies registered in total
as of 7 Sept 2026
26
countries with a recruiting site
as of 7 Sept 2026
5 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07746895
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
RecruitingPhase 2NCT06419205
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
RecruitingNCT07416162
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
RecruitingPhase 2NCT06209736
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 7 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new C3 glomerulonephritis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About C3 glomerulonephritis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (CFHR1, CFHR5, CFHR3, CFHR2).
Treatments being studied
1 approved treatment, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pegcetacoplan (Aspaveli)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).